Armando Genazzani

BIO AND EDUCATION

1993 Degree in Medicine and Surgery, Università di Catania

1997 D.Phil. (Oxford) University of Oxford (UK)

2002 Ph.D. by incorp (Cambridge), University of Cambridge (UK)

Over 130 publications with peer-review and impact factor above 2 with an aggregate impact factor of over 630

UNIVERSITY CAREER

2011-	Full Professor of Pharmacology, Università del Piemonte Orientale
2002-2011	Associate Professor of Pharmacology, Università del Piemonte Orientale
2000-2003	University Lecturer in Pharmacology and Clare Hall Fellow, University of Cambridge and Clare Hall College di Cambridge
1998-2000	Cambridge Pharmacology Fellow and BBSRC Pharmacology Fellow, University of Cambridge
1997-1998	EMBO Long-Term Fellow, Dept of Biochemistry, ETH, Zurich
1995-1997	Post-doctoral research fellow, Dept of Pharmacology, University of Oxford

UNIVERSITY POSITIONS

2016-	Vice-Rector for international activities, Università del Piemonte Orientale
2008-	Member of various University and Departmental Commitees, Università del Piemonte Orientale
2007-	Coordinator of a Master's Course in Regulatory Affairs and Market Access, Università del Piemonte Orientale

SCIENTIFIC POSITIONS

2015-	Member of the Technical and Scientific Committee of the Italian Medicines Agency (AIFA)
2014-	Member of the WHO Expert Advisory Panel on The International Pharmacopoeia and Pharmaceutical Preparations serving the INN Expert Group
2013-	Member of Ethical Review Board, Ospedale Maggiore della Carità (NO,VC,BI,VCO)
2013-2015	Member of the board of the Italian Society of Pharmacology (SIF)

MAIN FIELDS OF INTEREST

1. Intracellular calcium
2. Cellular metabolism
3. Nicotinamide phosphoribosyl transferase
4. Neurodegeneration
5. Pharmacogenetics and pharmacogenomics
6. Biosimilars
7. Drug discovery
8. Calcium channels as pharmacological targets

CURRENT ISSUES OF RESEARCH

1. **Oxaliplatin-induced peripheral neurotoxicity**

The aim of this project is to evaluate the mechanisms of action underlying the appearance of this side effect during cancer therapy, to assess whether there is a genetic predisposition, and to evaluate new drugs to combat neuropathy.

2. **NAMPT in cancer therapy and in inflammatory and autoimmune diseases**

Nicotinamide phosphoribosyl transferase is a key enzyme in NAD metabolism. The research group, starting from the hypothesis that metabolically active cells (such as those involved in inflammation and cancer cells) require high amounts of NAD and ATP, assesses the role of this enzyme in tumorigenesis, tumour-related inflammation and in inflammation. Furthermore, in collaboration with other groups (including Prof. Tron and Prof. Galli from the same Department), we develop specific inhibitors of this enzyme and investigate their therapeutic potential.

3. **Role of astrocytes in neurodegenerative diseases**

The group, starting from recent observations that show that astrocytes are involved in Alzheimer's disease, evaluates the possibility that these cells may have a pathogenetic involvement in neurodegenerative diseases with the ambition to develop therapeutic strategies related to these mechanisms.

4. **Rare diseases and calcium channels mutations**

In collaboration with Prof. Pirali, the group aims to identify molecules with therapeutic activities for some rare diseases related to gain- of-function defects in calcium channels.

5. **Pharmacogenetics**

In collaboration with Dr. Terrazzino and with several clinical groups, the ambition is to find genetics able to identify patients for whom some therapies are more effective compared to the

overall population or groups of patients for whom some therapies are less safe compared to the overall patient population.

CURRENT FUNDED PROJECTS

PROGRAMME	FUNDED PROJECT
Fondazione Cariplo 2013	"Understanding the pathogenesis of oxaliplatin-induced peripheral neurotoxicity"

TOP FIVE PAPERS

1. Genazzani AA, Carafoli E, Guerini D. 1999. Calcineurin controls inositol 1,4,5-trisphosphate type 1 receptor expression in neurons. Proceedings of the National Academy of Sciences of the United States of America 96:5797-5801.
2. Bak J, Billington RA, Timar G, Dutton AC, Genazzani AA. 2001. NAADP receptors are present and functional in the heart. Current biology 11:987-990.
3. Churchill GC, Okada Y, Thomas JM, Genazzani AA, Patel S, Galione A. 2002. NAADP mobilizes Ca^{2+} from reserve granules, lysosome-related organelles, in sea urchin eggs. Cell 111:703-708.
4. Billington RA, Genazzani AA, Travelli C, Condorelli F. 2008. NAD depletion by FK866 induces autophagy. Autophagy 4:385-387.
5. Stanic J, Carta M, Eberini I, Pelucchi S, Marcello E, Genazzani AA, Racca C, Mulle C, Di Luca M, Gardoni F. 2015. Rabphilin 3A retains NMDA receptors at synaptic sites through interaction with GluN2A/PSD-95 complex. Nat Commun6:10181.

AWARDS

1. Glaxo Prize for research on metabotropic glutamate receptors, 1991
2. *long-term fellowship* EMBO, 1997
3. Peter Baker fellowship for research on marine biology at the Marine biology Station of Plymouth, 1997
4. BBSRC David Phillips fellowship and grant, 2000
5. Royal Society fellowship and grant (declined), 2000
6. Galeno Prize for young scientists, 2008

FURTHER INFORMATION

www.genazzanilab.it
www.farmacogeneticanovara.it
https://scholar.google.it/citations?user=nzrp_cgAAAAJ